Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point. 

David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.

Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer. 

Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts. 

'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate. 

Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer. 

A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer. 

Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data. 

AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC. 

Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session.